The lack of a significant difference between MS and bone marrow samples for FLT3 mutations suggests that, while FLT3 may drive leukemic transformation in the marrow, its role in MS might be more in conjunction with the primary site and less site-dependent. Here, FLT3 is linked to myeloid sarcoma.